Satellos Bioscience Inc.
MSCL.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 4.28M | 1.51M | 3.21M | 1.60M | 736.00K |
| Gross Profit | -4.28M | -1.51M | -3.21M | -1.60M | -736.00K |
| SG&A Expenses | 8.83M | 8.03M | 7.52M | 6.86M | 6.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.02M | 26.46M | 24.49M | 22.22M | 20.75M |
| Operating Income | -30.02M | -26.46M | -24.49M | -22.22M | -20.75M |
| Income Before Tax | -28.36M | -24.70M | -21.91M | -22.73M | -21.58M |
| Income Tax Expenses | 142.00K | 172.00K | 114.00K | 95.00K | 63.00K |
| Earnings from Continuing Operations | -28.50 | -24.87 | -22.03 | -22.83 | -21.65 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.50M | -24.87M | -22.03M | -22.83M | -21.65M |
| EBIT | -30.02M | -26.46M | -24.49M | -22.22M | -20.75M |
| EBITDA | -30.02M | -26.46M | -24.48M | -22.21M | -20.74M |
| EPS Basic | -1.81 | -1.73 | -1.70 | -1.98 | -2.06 |
| Normalized Basic EPS | -1.13 | -1.07 | -1.06 | -1.04 | -1.09 |
| EPS Diluted | -1.81 | -1.73 | -1.70 | -1.98 | -2.06 |
| Normalized Diluted EPS | -1.13 | -1.07 | -1.06 | -1.04 | -1.09 |
| Average Basic Shares Outstanding | 62.11M | 57.50M | 52.07M | 47.55M | 42.68M |
| Average Diluted Shares Outstanding | 62.11M | 57.50M | 52.07M | 47.55M | 42.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |